DSMB Clears Clearmind to Test CMND-100 in Alcohol Use Disorder Patients
CMND sits 27% above its 52-week low of $1.43 on light trading volume (0.1× avg).
Summary
The independent Data and Safety Monitoring Board unanimously approved advancing CMND-100 into Parts B and C of the Phase 1/2 trial. This is the first time the drug will be tested in patients with moderate to severe alcohol use disorder, a critical efficacy milestone. Part B will enroll two cohorts of six patients at 80 mg and 160 mg doses to assess safety, tolerability, and early signs of reduced alcohol consumption and cravings. Part C will test a fixed 160 mg daily dose in healthy volunteers over five days. The stock rose 9% on the news, though it remains near its 52-week low. The company has a going concern warning and has relied on highly dilutive convertible note financings, so this clinical progress is essential to its survival.
At the time of this announcement, CMND was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $1.43 to $524.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.